HDAC9 and pulmonary arterial hypertension: Similarly, in 2012, Zhao et al. mitigated the development and pulmonary vascular remodeling of hypoxia-induced pulmonary hypertension using both VPA and suberoylanilide hydroxamic acid (vorinostat), an inhibitor of class I, II, and IV HDAC (7, 162).